Clinical Communications
Safety of COVID-19 vaccination in patients with polyethylene glycol allergy: A case series

https://doi.org/10.1016/j.jaip.2021.11.021Get rights and content

Cited by (0)

No funding has been received for this study.

Conflicts of interest: M. Fein has been on advisory boards and/or received consulting fees from ALK, Stallergenes, Medexus, Novartis, and Bausch Health. M. Blaquière has been on the advisory board of ALK and has received honoraria from Novartis, Medexus, ALK, and Starallergenes. M.-N. Primeau has been on Speakers' Bureau and/or advisory boards for ALK, Bausch Health, CSL Behring Canada, Mead Johnson, Medexus, Mylan, Novartis, Nutricia, Pediapharm, and Pfizer. The rest of the authors declare that they have no relevant conflicts of interest.

View Abstract